Publications in collaboration with researchers from Instituto Valenciano de Oncologia (13)

2023

  1. European Association of Urology biochemical recurrence risk groups after radical prostatectomy: external validation and identification of independent risk factors for progression and death

    Actas Urologicas Espanolas, Vol. 47, Núm. 7, pp. 422-429

  2. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

2019

  1. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance

    Prostate Cancer and Prostatic Diseases, Vol. 22, Núm. 1, pp. 84-90

2018

  1. Variability in the multicentre National Registry in Active Surveillance; a questionnaire for urologists

    Actas Urologicas Espanolas, Vol. 42, Núm. 7, pp. 442-449

2017

  1. Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España

    Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791

  2. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

    The Lancet Oncology, Vol. 18, Núm. 2, pp. 181-191

  3. The management of active surveillance in prostate cancer: Validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry

    Oncotarget, Vol. 8, Núm. 65, pp. 108451-108462

2016

  1. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 100, pp. 127-136

  2. Programa de monitorización de la vigilancia activa en cáncer de próstata en España de la Sociedad Española de Urología; resultados preliminares

    Actas Urologicas Espanolas, Vol. 40, Núm. 1, pp. 3-10

2014

  1. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options

    Actas Urologicas Espanolas

  2. Terapia focal en cáncer de próstata. Alternativas de tratamiento

    Actas Urologicas Espanolas

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2005

  1. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

    Journal of Urology, Vol. 174, Núm. 4 I, pp. 1242-1247